OUTSOURCED DRUG DISCOVERY & DEVELOPMENT PLATFORM

relationshp_solo3

RxCelerate: Architects of Drug Development

RxCelerate is an outsourced drug discovery and development platform. Our experienced leadership team will design and deliver on integrated programs to drive your asset through drug discovery, preclinical research and beyond. We specialise in bespoke experimental design with data-rich endpoints; maximising your chances of reaching the clinic.

ENDPOINTS NEWS: Forget about greed, President Trump: the villain responsible for high drug prices is inefficiency - by David Grainger

PRESS RELEASE: RxCelerate acquires cutting-edge molecular modelling company Prosarix

PRESS RELEASE: RxCelerate Opens UK-Based Chemistry Operations at the University of Warwick

PRESS RELEASE: RxCelerate acquires The Cambridge Partnership Ltd for £1.45 million as Nick Tait joins as Chief Financial Officer

PRESS RELEASE: RxCelerate acquires specialist bioanalytical CRO Total Scientific Ltd

DrugBaron Button

Our clients range from entirely virtual start-ups, using RxCelerate as their infrastructure, through to 3 of the top 15 global pharmaceutical companies


SOME OF OUR CLIENTS

WHAT PEOPLE ARE SAYING ABOUT RxCELERATE

It’s such a pleasure, working with partners in whom you have complete trust. RxCelerate has added value to many of our programs and we have no hesitation recommending them to our friends.

Kevin Johnson

Partner, Medicxi Ventures

Levicept, a biotechnology company developing a novel agent (LEVI-04) for the treatment of osteoarthritis, has been working with RxCelerate for in excess of 3 years.  RxCelerate is a key partner in the development of LEVI-04 and indeed Jill and the team have helped identify and develop bespoke models of osteoarthritis that underpin the translation to man, mechanism(s) of action and subsequently the progression of LEVI-04 to Phase 1clinical trials. 

RxCelerate is more than a CRO but an extension of Levicept’s development team.  RxCelerate adds significant value to our programme by understanding the background science in great depth. Jill and the team are able to provide a service that few CROs are capable of matching.  

I would highly recommend RxCelerate to any pharmaceutical or biotechnology company seeking a contract research organisation that provides exceptionally high quality data, outstanding animal ethical standards, scientific know-how and most importantly a CRO that takes the time to understand the science and consequently helps develop models that meet your scientific and translational goals.

Simon Westbrook

CEO, Levicept

RxCelerate was instrumental in the success of XO1. They should be your first port of call for those critical experiments upon which the value and decision-making of your company or programme depend. Jill Reckless is an experimental biologist of the highest order and Jill and her team are wonderfully obsessive about flawless experimental design and execution. They particularly excel in the area of novel model systems where no precedents exist, or where current models are inadequate and need to be re-designed.

Richard Mason

CEO, XO1

CONTACT US

RxCelerate US

One Broadway
14th Floor
Cambridge, MA 02142

RxCelerate UK

Babraham Research Campus, Babraham, Cambridge
CB22 3AT UK

+44 [0]1223 839557
Fill out this field
Fill out this field
Fill out this field
Fill out this field
UK and US Office

FOLLOW US

Twitter UK
Twitter US
Menu